Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 120

1.

Characterization CYP1A2, CYP2C9, CYP2C19 and CYP2D6 polymorphisms using HRMA in Psychiatry patients with schizophrenia and bipolar disease for personalized medicine.

Yenilmez ED, Tamam L, Karaytug O, Tuli A.

Comb Chem High Throughput Screen. 2018 Jun 19. doi: 10.2174/1386207321666180619164726. [Epub ahead of print]

PMID:
29921201
2.

Response to Agomelatine Treatment is Independent of Smoking Status and Dosage: Results From the AGOPSYCH Study.

Englisch S, Jung HS, Lewien A, Becker A, Nowak U, Braun H, Eisenacher S, Thiem J, Meyer-Lindenberg A, Zink M.

Pharmacopsychiatry. 2018 May 7. doi: 10.1055/a-0606-5240. [Epub ahead of print]

PMID:
29734455
3.

Clozapine Therapy and CYP2D6, CYP1A2, and CYP3A4 Genotypes.

Dean L.

In: Pratt V, McLeod H, Rubinstein W, Dean L, Malheiro A, editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012-.
2016 Jun 8.

4.

Pharmacogenomic Testing for Psychotropic Medication Selection: A Systematic Review of the Assurex GeneSight Psychotropic Test.

Health Quality Ontario .

Ont Health Technol Assess Ser. 2017 Apr 11;17(4):1-39. eCollection 2017. Review.

5.

Adjunctive Minocycline in Clozapine-Treated Patients with Schizophrenia: Analyzing the Effects of Minocycline on Clozapine Plasma Levels.

Wehring HJ, Elsobky T, McEvoy JP, Vyas G, Richardson CM, McMahon RP, DiPaula BA, Liu F, Sullivan K, Buchanan RW, Feldman S, McMahon EM, Kelly DL.

Psychiatr Q. 2018 Mar;89(1):73-80. doi: 10.1007/s11126-017-9515-x.

PMID:
28466366
6.

Pharmacoepigenomic responses of antipsychotic drugs on pharmacogenes are likely to be modulated by miRNAs.

Swathy B, Saradalekshmi KR, Nair IV, Nair C, Banerjee M.

Epigenomics. 2017 Jun;9(6):811-821. doi: 10.2217/epi-2016-0181. Epub 2017 Apr 21.

PMID:
28429622
7.

Potential Role of Patients' CYP3A-Status in Clozapine Pharmacokinetics.

Tóth K, Csukly G, Sirok D, Belic A, Kiss Á, Háfra E, Déri M, Menus Á, Bitter I, Monostory K.

Int J Neuropsychopharmacol. 2017 Jul 1;20(7):529-537. doi: 10.1093/ijnp/pyx019.

8.

Potential Mechanisms of Hematological Adverse Drug Reactions in Patients Receiving Clozapine in Combination With Proton Pump Inhibitors.

Wiciński M, Węclewicz MM, Miętkiewicz M, Malinowski B, Grześk E, Klonowska J.

J Psychiatr Pract. 2017 Mar;23(2):114-120. doi: 10.1097/PRA.0000000000000223. Review.

PMID:
28291036
9.

[Therapeutic drug monitoring of olanzapine].

Djerada Z, Brousse G, Niel P, Llorca PM, Eschalier A, Bentue-Ferrer D, Libert F; groupe suivi thérapeutique pharmacologique de la Société française de pharmacologie et de thérapeutique.

Therapie. 2016 Oct 25. pii: S0040-5957(16)30042-7. doi: 10.2515/therapie/2015040. [Epub ahead of print] French.

PMID:
27793422
10.

[Therapeutic drug monitoring of clozapine].

Djerada Z, Daviet F, Llorca PM, Eschalier A, Saint-Marcoux F, Bentué-Ferrer D, Libert F; Groupe suivi thérapeutique pharmacologique de la Société française de pharmacologie et de thérapeutique.

Therapie. 2016 Aug 24. pii: S0040-5957(16)31132-5. doi: 10.2515/therapie/2015041. [Epub ahead of print] French.

PMID:
27771104
11.

Genetic Determinants of Clozapine-Induced Metabolic Side Effects.

Vasudev K, Choi YH, Norman R, Kim RB, Schwarz UI.

Can J Psychiatry. 2017 Feb;62(2):138-149. doi: 10.1177/0706743716670128. Epub 2016 Sep 29.

12.

Cigarette smoking has a differential effect on the plasma level of clozapine in Taiwanese schizophrenic patients associated with the CYP1A2 gene -163A/C single nucleotide polymorphism.

Huang HC, Lua AC, Wu LS, Wu BJ, Lee SM, Liu CZ.

Psychiatr Genet. 2016 Aug;26(4):172-7. doi: 10.1097/YPG.0000000000000139.

PMID:
27203225
13.

CYP1A2 and CYP2D6 Gene Polymorphisms in Schizophrenic Patients with Neuroleptic Drug-Induced Side Effects.

Ivanova SA, Filipenko ML, Vyalova NM, Voronina EN, Pozhidaev IV, Osmanova DZ, Ivanov MV, Fedorenko OY, Semke AV, Bokhan NA.

Bull Exp Biol Med. 2016 Mar;160(5):687-90. doi: 10.1007/s10517-016-3250-4. Epub 2016 Mar 29.

PMID:
27021090
14.

Ultrarapid clozapine metabolism and CYP2D6 gene duplication in a patient with schizophrenia.

Caetano D, Piatkov I.

Per Med. 2016 Mar;13(2):113-117. doi: 10.2217/pme.15.56. Epub 2016 Feb 8.

PMID:
29749897
15.

The CYP1A2 -163C > A polymorphism is associated with super-refractory schizophrenia.

de Brito RB, de Carvalho Araújo L, Diniz MJA, de Castro Georg R, Nabout JC, Vianelo RP, da Silva Santos R, da Silva Cruz AH, Ghedini PC.

Schizophr Res. 2015 Dec;169(1-3):502-503. doi: 10.1016/j.schres.2015.10.018. Epub 2015 Oct 31. No abstract available.

PMID:
26530626
16.

Currently recognized genes for schizophrenia: High-resolution chromosome ideogram representation.

Butler MG, McGuire AB, Masoud H, Manzardo AM.

Am J Med Genet B Neuropsychiatr Genet. 2016 Mar;171B(2):181-202. doi: 10.1002/ajmg.b.32391. Epub 2015 Oct 13.

PMID:
26462458
17.

Pharmacogenetics of clozapine treatment response and side-effects in schizophrenia: an update.

Sriretnakumar V, Huang E, Müller DJ.

Expert Opin Drug Metab Toxicol. 2015;11(11):1709-31. doi: 10.1517/17425255.2015.1075003. Epub 2015 Sep 12. Review.

PMID:
26364648
18.

In Vitro Characterization of the Human Liver Microsomal Kinetics and Reaction Phenotyping of Olanzapine Metabolism.

Korprasertthaworn P, Polasek TM, Sorich MJ, McLachlan AJ, Miners JO, Tucker GT, Rowland A.

Drug Metab Dispos. 2015 Nov;43(11):1806-14. doi: 10.1124/dmd.115.064790. Epub 2015 Sep 1.

19.

[Therapeutic Drug Monitoring of Clozapine].

Djerada Z, Daviet F, Llorca PM, Eschalier A, Saint-Marcoux F, Bentué-Ferrer D, Libert F.

Therapie. 2015 Jul 28. [Epub ahead of print] French.

PMID:
26220922
20.

[Therapeutic Drug Monitoring of Olanzapine].

Djerada Z, Brousse G, Niel P, Llorca PM, Eschalier A, Bentue-Ferrer D, Libert F.

Therapie. 2015 Jul 28. [Epub ahead of print] French.

PMID:
26220921

Supplemental Content

Loading ...
Support Center